<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724421</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-041</org_study_id>
    <nct_id>NCT04724421</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol for Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options</brief_title>
  <official_title>An Open-label, Expanded Access Protocol for Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <brief_summary>
    <textblock>
      The intent of this open-label, multicenter Expanded Access Program (EAP) is to provide early&#xD;
      access to treatment with voxelotor prior to market authorization for pediatric patients age 4&#xD;
      to 11 years with sickle cell disease (SCD) who have no alternative treatment options and are&#xD;
      ineligible to participate in clinical trials of voxelotor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients who are eligible for participation in this EAP will be treated with&#xD;
      voxelotor, dispersible tablets or powder for oral suspension administered orally once daily&#xD;
      (QD) at a weight-based dose, and followed by the treating physicians at the participating&#xD;
      sites. Participants will receive standard of care treatment and procedures for management of&#xD;
      SCD, including an initial visit and routine visits at least every 12 weeks (± 7 days) for&#xD;
      clinical and laboratory assessments per standard of care and re-supply of voxelotor. A safety&#xD;
      follow-up visit will be conducted 28 days (± 7 days) after the last dose of investigational&#xD;
      product.&#xD;
&#xD;
      This EAP may continue until such time that voxelotor is commercially available for patients&#xD;
      age 4 to 11 years, or the Sponsor discontinues the voxelotor EAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Sickle Cell Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voxelotor</intervention_name>
    <description>synthetic small molecule</description>
    <other_name>GBT440</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of sickle cell disease of any genotype&#xD;
&#xD;
          2. Ineligible or unable to participate in actively recruiting clinical studies of&#xD;
             voxelotor&#xD;
&#xD;
          3. Baseline hemoglobin (Hb) ≤10.5 g/dL&#xD;
&#xD;
          4. No alternative treatment options in the judgement of the treating Investigator&#xD;
&#xD;
          5. Participants who, if female of childbearing potential (post-menarche), and are&#xD;
             sexually active, agree to use highly effective methods of contraception from study&#xD;
             start to 30 days after the last dose of voxelotor&#xD;
&#xD;
          6. Written informed parental/guardian consent and participant assent (if applicable) has&#xD;
             been obtained per Institutional Review Board (IRB) policy and requirements, consistent&#xD;
             with International Council for Harmonisation (ICH) guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving chronic red blood cell (RBC) transfusion therapy for primary or secondary&#xD;
             stroke prevention&#xD;
&#xD;
          2. Hepatic dysfunction characterized by alanine aminotransferase (ALT) &gt;4 × the upper&#xD;
             limit of normal (ULN) for age&#xD;
&#xD;
          3. Severe renal dysfunction (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73&#xD;
             m2 by Schwartz formula)&#xD;
&#xD;
          4. Clinically significant bacterial, fungal, parasitic, or viral infection that requires&#xD;
             therapy:&#xD;
&#xD;
               1. Patients with acute bacterial infection requiring antibiotic use should delay&#xD;
                  screening/enrollment until the course of antibiotic therapy has been completed.&#xD;
&#xD;
               2. Patients with known active hepatitis A, B, or C or who are known to be Human&#xD;
                  Immunodeficiency Virus (HIV) positive&#xD;
&#xD;
          5. Any condition affecting drug absorption, such as major surgery involving the stomach&#xD;
             or small intestine (prior cholecystectomy is acceptable)&#xD;
&#xD;
          6. Female who is pregnant or breastfeeding&#xD;
&#xD;
          7. Participated in another clinical trial of an investigational drug or medical device,&#xD;
             within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior&#xD;
             to informed consent for the EAP, or is currently participating in another trial of an&#xD;
             investigational drug or medical device&#xD;
&#xD;
          8. Medical, psychological, or behavioral conditions, that, in the opinion of the&#xD;
             Investigator, may preclude informed consent, safe participation, or compliance with&#xD;
             the protocol procedures&#xD;
&#xD;
          9. Use of herbal medications (eg, St. John's wort), sensitive cytochrome P450 (CYP) 3A4&#xD;
             substrates with a narrow therapeutic index, or strong CYP3A4 inducers&#xD;
&#xD;
         10. Active symptomatic COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Julia Martinisi</last_name>
    <phone>650-452-7918</phone>
    <email>jmartinisi@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Xu, MD</last_name>
    <phone>650-534-2574</phone>
    <email>mxu@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Erica Seiber</last_name>
      <phone>602-933-0171</phone>
      <email>esieber@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Sanjay Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady's Children Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Mehrzad Milburn</last_name>
      <phone>858-966-1700</phone>
      <phone_ext>228155</phone_ext>
      <email>mmilburn@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Jenny Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Stephanie Margulies</last_name>
      <phone>202-476-2281</phone>
      <email>Stefanie.Margulies@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Deepika Darbari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sarah Acado</last_name>
      <email>s.acado@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Ofelia Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Stacey Ladd</last_name>
      <phone>404-785-8863</phone>
      <email>Stacy.Ladd@choa.org</email>
    </contact>
    <investigator>
      <last_name>Clark Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Krystle Stone</last_name>
      <phone>706-721-3626</phone>
      <email>Kstone6@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Nnenna Badamosi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Theresa Ryan- Knapp, RN</last_name>
      <phone>912-350-5645</phone>
      <email>Theresa.ryan@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Pendelton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana hemophilia and thrombosis center, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Adrianna Williamson</last_name>
      <phone>317-372-9491</phone>
      <email>awilliamson@ihtc.org</email>
    </contact>
    <investigator>
      <last_name>Emily Meier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine-Sickle Cell Center of Southern Louisiana</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Melody Benton</last_name>
      <phone>504-988-3596</phone>
      <email>mbenton@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Amina Rafique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>BreAnna Simpson</last_name>
      <phone>734-615-4630</phone>
      <email>sbreanna@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sabeena Hussain</last_name>
      <phone>973-926-3136</phone>
      <email>Sabeena.Hussain@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Shalu Narang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BronxCare Health System</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Diane Strome</last_name>
      <phone>718-960-1020</phone>
      <email>DStrom@bronxleb.org</email>
    </contact>
    <contact_backup>
      <last_name>Ana Maria Emeh</last_name>
      <phone>718-960-4498</phone>
      <email>anaemeh@bronxleb.org</email>
    </contact_backup>
    <investigator>
      <last_name>Howard Grodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYC Health and Hospitals</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Raven Dwyer</last_name>
      <phone>917-608-5758</phone>
      <email>dwyerr1@nychhc.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Rivlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Kathryn DiFrancesco</last_name>
      <phone>216-844-8535</phone>
      <email>Kathryn.DiFrancesco@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amma Owusu-Ansah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Earleisha Mack</last_name>
      <phone>843-792-2957</phone>
      <email>feldere@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Shayla Bergmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tranaka Fuqua</last_name>
      <phone>864-455-5158</phone>
      <email>tranaka.fuqua@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Alan Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeremie Estepp, MD</last_name>
      <phone>866-278-5833</phone>
      <email>Jeremie.estepp@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Jeremie Estepp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Dennis Carson</last_name>
      <phone>817-372-9259</phone>
      <email>Dennis.Carson@cookchildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Lynn Davisson</last_name>
      <phone>817-372-9259</phone>
      <email>Lynn.davisson@cookchildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Clarissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Specialists of Virginia</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Vivian Phan</last_name>
      <email>vivianphan@gwmail.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

